{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:12:36Z","timestamp":1790518356654,"version":"4.1.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Expression of the cell cycle regulatory gene CDK6 is required for Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) cell growth, whereas expression of the closely related CDK4 protein is dispensable. Moreover, CDK6 silencing is more effective than treatment with the dual CDK4\/6 inhibitor palbociclib in suppressing Ph+ ALL in mice, suggesting that the growth-promoting effects of CDK6 are, in part, kinase-independent in Ph+ ALL. Accordingly, we developed CDK4\/6\u2013targeted proteolysis-targeting chimeras (PROTACs) that inhibit CDK6 enzymatic activity in vitro, promote the rapid and preferential degradation of CDK6 over CDK4 in Ph+ ALL cells, and markedly suppress S-phase cells concomitant with inhibition of CDK6-regulated phospho-RB and FOXM1 expression. No such effects were observed in CD34+ normal hematopoietic progenitors, although CDK6 was efficiently degraded. Treatment with the CDK6-degrading PROTAC YX-2-107 markedly suppressed leukemia burden in mice injected with de novo or tyrosine kinase inhibitor\u2013resistant primary Ph+ ALL cells, and this effect was comparable or superior to that of the CDK4\/6 enzymatic inhibitor palbociclib. These studies provide \u201cproof of principle\u201d that targeting CDK6 with PROTACs that inhibit its enzymatic activity and promote its degradation represents an effective strategy to exploit the \u201cCDK6 dependence\u201d of Ph+ ALL and, perhaps, of other hematologic malignancies. Moreover, they suggest that treatment of Ph+ ALL with CDK6-selective PROTACs would spare a high proportion of normal hematopoietic progenitors, preventing the neutropenia induced by treatment with dual CDK4\/6 inhibitors.<\/jats:p>","DOI":"10.1182\/blood.2019003604","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T16:56:26Z","timestamp":1581353786000},"page":"1560-1573","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs"],"prefix":"10.1182","volume":"135","author":[{"given":"Marco","family":"De Dominici","sequence":"first","affiliation":[{"name":"Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Porazzi","sequence":"first","affiliation":[{"name":"Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcai","family":"Xiao","sequence":"first","affiliation":[{"name":"The Wistar Institute, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Chao","sequence":"first","affiliation":[{"name":"The Wistar Institute, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yao","family":"Tang","sequence":"first","affiliation":[{"name":"The Wistar Institute, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fortina","sequence":"first","affiliation":[{"name":"Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0374-1536","authenticated-orcid":false,"given":"Orietta","family":"Spinelli","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy;"},{"name":"Department of Oncology and Hematology-Oncology, Universit\u00e0 Statale Milano, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke F.","family":"Peterson","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Petruk","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Barletta","sequence":"first","affiliation":[{"name":"Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mazo","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Cingolani","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Salvino","sequence":"first","affiliation":[{"name":"The Wistar Institute, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Calabretta","sequence":"first","affiliation":[{"name":"Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2020043011240910200_B1","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","article-title":"Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia","volume":"91","author":"Faderl","year":"1998","journal-title":"Blood"},{"issue":"4946","key":"2020043011240910200_B2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"issue":"6","key":"2020043011240910200_B3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020043011240910200_B4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2020043011240910200_B5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","article-title":"Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"2020043011240910200_B6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1158\/0008-5472.CAN-17-2644","article-title":"Targeting CDK6 and BCL2 exploits the \u201cMYB addiction\u201d of Ph+ acute lymphoblastic leukemia","volume":"78","author":"De Dominici","year":"2018","journal-title":"Cancer Res"},{"issue":"15","key":"2020043011240910200_B7","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"2020043011240910200_B8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/1535-7163.MCT-14-1065","article-title":"Specific antileukemic activity of PD0332991, a CDK4\/6 inhibitor, against Philadelphia-chromosome-positive lymphoid leukemia","volume":"15","author":"Nemoto","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2020043011240910200_B9","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1038\/sj.emboj.7601675","article-title":"Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C\/EBPalpha interaction","volume":"26","author":"Fujimoto","year":"2007","journal-title":"EMBO J"},{"issue":"2","key":"2020043011240910200_B10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2013.07.012","article-title":"A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis [published correction appears in Cancer Cell. 2016;30(2):359-360]","volume":"24","author":"Kollmann","year":"2013","journal-title":"Cancer Cell"},{"issue":"1","key":"2020043011240910200_B11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","article-title":"CDK6 as a key regulator of hematopoietic and leukemic stem cell activation [published correction appears in Blood. 2015;(1):90-101]","volume":"125","author":"Scheicher","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2020043011240910200_B12","doi-asserted-by":"crossref","first-page":"e51847","DOI":"10.1371\/journal.pone.0051847","article-title":"Cyclin-dependent kinase 6 phosphorylates NF-\u03baB P65 at serine 536 and contributes to the regulation of inflammatory gene expression","volume":"7","author":"Buss","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"2020043011240910200_B13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molcel.2013.12.002","article-title":"Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-\u03baB-dependent gene expression [published correction appears in Mol Cell. 2014 Feb 20;53(4):682.]","volume":"53","author":"Handschick","year":"2014","journal-title":"Mol Cell"},{"issue":"15","key":"2020043011240910200_B14","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood-2018-08-872648","article-title":"CDK6 coordinates JAK2V617F mutant MPN via NF-\u03baB and apoptotic networks","volume":"133","author":"Uras","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2020043011240910200_B15","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1158\/2159-8290.CD-17-0912","article-title":"CDK6 antagonizes p53-induced responses during tumorigenesis","volume":"8","author":"Bellutti","year":"2018","journal-title":"Cancer Discov"},{"issue":"7658","key":"2020043011240910200_B16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature22797","article-title":"The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival","volume":"546","author":"Wang","year":"2017","journal-title":"Nature"},{"issue":"35","key":"2020043011240910200_B17","doi-asserted-by":"crossref","first-page":"25644","DOI":"10.1074\/jbc.M600197200","article-title":"Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression","volume":"281","author":"Spofford","year":"2006","journal-title":"J Biol Chem"},{"issue":"4","key":"2020043011240910200_B18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2020043011240910200_B19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2020043011240910200_B20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"17","key":"2020043011240910200_B21","doi-asserted-by":"crossref","first-page":"11269","DOI":"10.1021\/acs.chemrev.7b00077","article-title":"Small-molecule modulation of protein homeostasis","volume":"117","author":"Burslem","year":"2017","journal-title":"Chem Rev"},{"issue":"16","key":"2020043011240910200_B22","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"issue":"6","key":"2020043011240910200_B23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"2020043011240910200_B24","first-page":"447","article-title":"Establishment of a Ph1-positive human cell line (BV173)","volume":"70","author":"Pegoraro","year":"1983","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"2020043011240910200_B25","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1158\/0008-5472.CAN-18-0195","article-title":"Targeting STAT5 or STAT5-regulated pathways suppresses leukemogenesis of Ph+ acute lymphoblastic leukemia","volume":"78","author":"Minieri","year":"2018","journal-title":"Cancer Res"},{"issue":"5","key":"2020043011240910200_B26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ccr.2011.10.001","article-title":"A systematic screen for CDK4\/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells","volume":"20","author":"Anders","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"2020043011240910200_B27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41467-017-00830-y","article-title":"NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia","volume":"8","author":"M\u00e4rklin","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2020043011240910200_B28","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41467-018-04620-y","article-title":"SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity","volume":"9","author":"Yao","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"2020043011240910200_B29","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2141.2008.07261.x","article-title":"An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase","volume":"142","author":"Kohlmann","year":"2008","journal-title":"Br J Haematol"},{"issue":"15","key":"2020043011240910200_B30","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","article-title":"Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group","volume":"28","author":"Haferlach","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"2020043011240910200_B31","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1021\/jm0600388","article-title":"Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition","volume":"49","author":"Lu","year":"2006","journal-title":"J Med Chem"},{"issue":"10","key":"2020043011240910200_B32","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2020043011240910200_B33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ejmech.2016.07.020","article-title":"New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities","volume":"122","author":"Wang","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"6241","key":"2020043011240910200_B34","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"10","key":"2020043011240910200_B35","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL\/HIF-1\u03b1 interaction","volume":"134","author":"Buckley","year":"2012","journal-title":"J Am Chem Soc"},{"issue":"2","key":"2020043011240910200_B36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","article-title":"Homolog-selective degradation as a strategy to probe the function of CDK6 in AML","volume":"26","author":"Brand","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"3","key":"2020043011240910200_B37","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bbrc.2016.06.091","article-title":"Nuclear cereblon modulates transcriptional activity of Ikaros and regulates its downstream target, enkephalin, in human neuroblastoma cells","volume":"477","author":"Wada","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"2020043011240910200_B38","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/ml4000657","article-title":"Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development","volume":"4","author":"Vu","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"2020043011240910200_B39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"issue":"10","key":"2020043011240910200_B40","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","article-title":"Selective inhibition of HDAC1 and HDCA2 as a potential therapeutic option for B-ALL","volume":"21","author":"Stubbs","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2020043011240910200_B41","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2020043011240910200_B42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"2020043011240910200_B43","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders","volume":"62","author":"Su","year":"2019","journal-title":"J Med Chem"},{"issue":"11","key":"2020043011240910200_B44","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.bmcl.2019.03.035","article-title":"Selective degradation of CDK6 by a palbociclib based PROTAC","volume":"29","author":"Rana","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"19","key":"2020043011240910200_B45","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1002\/anie.201901336","article-title":"Development of dual and selective degraders of cyclin-dependent kinases 4 and 6","volume":"58","author":"Jiang","year":"2019","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/18\/1560\/1725347\/bloodbld2019003604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/18\/1560\/1725347\/bloodbld2019003604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T05:12:12Z","timestamp":1665810732000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/18\/1560\/441044\/Selective-inhibition-of-Phpositive-ALL-cell-growth"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":45,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,4,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003604","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]}}}